|
|
|
|
| Symbol(s): |
OREX |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
OREX has a current Overall Rating of C (Neutral). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| OREX has a current Overall Rating of C (Neutral). Power Rating (81) is very high; appreciation potential (6) is negative. Relative to the S&P 500 Composite, Orexigen Therapeutics Inc has both Growth and Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. OREX is of average investment quality. OREX's current technical position is mixed. OREX's Power Rating is 81. The recent trend in OREX's earnings estimates has been favorable. OREX's Biological...
| | |
|
|
